Vimta Labs Share Price Gains Over 3% After Q1 FY27 Net Profit Rises 11.4% to Rs 21.04 Crore
- July 21, 2026
- Posted by: Neeraj Pandey
- Category: News
Vimta Labs share price up 3.16% at Rs 547.00. Q1 FY27 net profit Rs 21.04 crore, up 11.4% YoY. Revenue Rs 109.07 crore, up 11.85% YoY.
The Vimta Labs share price gained over 3 percent on 21 July 2026 after the contract research and testing organisation reported steady Q1 FY27 growth, with net profit rising 11.4 percent year on year to Rs 21.04 crore on revenue growth of 11.85 percent to Rs 109.07 crore.
Click Here – Get Free Investment Predictions
About Vimta Labs
Vimta Labs is a prominent Indian contract research and testing organisation, providing clinical and pre-clinical research, analytical testing, advanced molecular biology, and environmental testing services to pharmaceutical and agrochemical clients.
The company supports regulatory authorities through mandatory certification of food and agricultural products for export from India, giving it a diversified revenue base across pharmaceutical, food safety, and environmental testing segments.
Vimta Labs has built a reputation for quality and regulatory compliance over multiple decades, which supports steady long term client relationships and underpins the consistency reflected in the Vimta Labs share price growth trend.
Vimta Labs Q1 FY27 Results: Key Numbers
| Metric | Q1 FY27 | YoY Change |
|---|---|---|
| Net Profit (Q1 FY27) | Rs 21.04 crore | Up 11.4% YoY from Rs 18.89 crore |
| Revenue from Operations | Rs 109.07 crore | Up 11.85% YoY from Rs 97.56 crore |
| Total Income | Rs 112.89 crore | Up 13.7% YoY |
| Earnings Per Share (EPS) | Rs 4.71 | Up from Rs 4.25 YoY |
The Vimta Labs share price gain reflects a quarter of steady, consistent growth rather than a dramatic beat, with revenue and profit both growing in the low double digits, a pattern typical for a mature contract research organisation with a diversified client base.
Sequential revenue remained largely stable compared to Rs 109.25 crore in Q4 FY26, indicating the business is operating at a consistent run rate rather than showing significant seasonality, a characteristic that investors in testing and research services businesses often value for earnings predictability.
Total income growth of 13.7 percent, ahead of the 11.85 percent revenue growth, suggests a modest contribution from other income sources, while EPS growth from Rs 4.25 to Rs 4.71 confirms the profit growth is flowing through proportionately to shareholders without dilution concerns for the Vimta Labs share price.
Consult a SEBI Registered Investment Advisor on Univest
Why Vimta Labs Share Price Is Reacting
The Vimta Labs share price is reacting positively to a quarter of dependable, if unspectacular, growth, which tends to be well received in contract research and testing businesses where investors prioritise consistency and regulatory compliance track record over headline growth rates.
Steady demand across clinical research, food and agricultural export certification, and environmental testing services provides Vimta Labs with revenue diversification that reduces dependence on any single end market’s cyclicality.
The company’s role in mandatory certification for food and agricultural exports gives it a somewhat regulatory-anchored revenue stream, which likely supports investor confidence in the durability of the Vimta Labs share price growth trajectory.
Outlook for Vimta Labs Share Price
Investors tracking the Vimta Labs share price should watch for any new client wins or capacity expansion announcements in the clinical research and testing segments, since incremental capacity has historically been the main lever for accelerating growth beyond the current steady pace.
India’s growing pharmaceutical and agrochemical export sector continues to require third party testing and certification services, providing a structural demand backdrop for Vimta Labs’ core business over the medium term.
Margin trends will be worth monitoring in coming quarters, since testing and research businesses can see margin expansion as fixed laboratory infrastructure costs get spread across a growing revenue base, a dynamic that could support further upside for the Vimta Labs share price.
Download the Univest iOS App or Univest Android App to track Vimta Labs share price live and get instant Q1 result alerts.
Conclusion
Vimta Labs delivered a steady Q1 FY27, with net profit up 11.4 percent to Rs 21.04 crore on revenue growth of 11.85 percent, lifting the Vimta Labs share price over 3 percent on 21 July 2026. The consistency of growth across the contract research and testing business, combined with a diversified client base spanning pharmaceuticals, food exports, and environmental testing, supports a steady investment case. Consult a SEBI registered adviser before acting on the Vimta Labs share price.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Vimta Labs Q1 FY27 Results
Why did Vimta Labs share price rise on 21 July 2026?
Ans. The Vimta Labs share price rose over 3 percent after the company reported Q1 FY27 net profit of Rs 21.04 crore, up 11.4 percent year on year, on revenue growth of 11.85 percent to Rs 109.07 crore.
What business does Vimta Labs operate?
Ans. Vimta Labs is a contract research and testing organisation providing clinical and pre-clinical research, analytical testing, molecular biology, and environmental testing services, along with food and agricultural export certification.
What was Vimta Labs’s EPS growth in Q1 FY27?
Ans. Basic earnings per share grew from Rs 4.25 in Q1 FY26 to Rs 4.71 in Q1 FY27, reflecting proportionate profit growth without shareholder dilution.
Is Vimta Labs’ revenue seasonal?
Ans. Revenue remained largely stable sequentially compared to the preceding quarter, suggesting the business operates at a consistent run rate rather than showing significant seasonality.
What end markets does Vimta Labs serve?
Ans. The company serves pharmaceutical, food and agricultural export certification, and environmental testing markets, providing revenue diversification across multiple demand sources.
Is Vimta Labs share price a buy after the Q1 results?
Ans. This article does not constitute investment advice. The growth was steady and consistent, but investors should evaluate valuation and consult a SEBI registered adviser before acting on the Vimta Labs share price.
Where can I track Vimta Labs share price live?
Ans. You can track the Vimta Labs share price live on the Univest app and website, along with quarterly result alerts and research on healthcare and testing services stocks.
